{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T19:41:44Z","timestamp":1770579704507,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10815-024-03296-2","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:02:00Z","timestamp":1729263720000},"page":"3387-3398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of follicle-stimulating hormone dose on the risk of being classified as suboptimal responders according to the POSEIDON criteria"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-409X","authenticated-orcid":false,"given":"Alyssa","family":"Hochberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Yarali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan N.","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro C.","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"3296_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fendo.2019.00281","volume":"10","author":"V Grisendi","year":"2019","unstructured":"Grisendi V, Mastellari E, La Marca A. Ovarian reserve markers to identify poor responders in the context of poseidon classification. Front Endocrinol (Lausanne). 2019;10:281 (https:\/\/pubmed-ncbi-nlm-nih-gov.sheba.idm.oclc.org\/31139145\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/humupd\/dmq034","volume":"17","author":"SL Broer","year":"2011","unstructured":"Broer SL, D\u00f3lleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17:46\u201354 (https:\/\/pubmed.ncbi.nlm.nih.gov\/20667894\/).","journal-title":"Hum Reprod Update."},{"key":"3296_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/humupd\/dms041","volume":"19","author":"SL Broer","year":"2013","unstructured":"Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19:26\u201336 (https:\/\/pubmed.ncbi.nlm.nih.gov\/23188168\/).","journal-title":"Hum Reprod Update."},{"key":"3296_CR4","doi-asserted-by":"crossref","unstructured":"Esteves SC, Humaidan P, Alviggi C, Fischer R. The novel POSEIDON stratification of \u201cLow prognosis patients in Assisted Reproductive Technology\u201d and its proposed marker of successful outcome. F1000Res. 2016;5. https:\/\/pubmed.ncbi.nlm.nih.gov\/28232864\/","DOI":"10.12688\/f1000research.10382.1"},{"key":"3296_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","volume":"105","author":"C Alviggi","year":"2016","unstructured":"Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452\u20133 (https:\/\/pubmed.ncbi.nlm.nih.gov\/26921622\/).","journal-title":"Fertil Steril."},{"issue":"14","key":"3296_CR6","first-page":"1","volume":"2023","author":"I Feferkorn","year":"2023","unstructured":"Feferkorn I, Ata B, Esteves SC, La Marca A, Paulson R, Blockeel C, et al. The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization. J Assist Reprod Genet. 2023;2023(14):1\u201311 (https:\/\/link-springer-com.proxy3.library.mcgill.ca\/article\/10.1007\/s10815-023-02757-4).","journal-title":"J Assist Reprod Genet"},{"key":"3296_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","volume":"26","author":"AP Ferraretti","year":"2011","unstructured":"Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of \u201cpoor response\u201d to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616\u201324 (https:\/\/pubmed.ncbi.nlm.nih.gov\/21505041\/).","journal-title":"Hum Reprod."},{"key":"3296_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.fertnstert.2017.09.024","volume":"109","author":"A Boza","year":"2018","unstructured":"Boza A, Oguz SY, Misirlioglu S, Yakin K, Urman B. Utilization of the Bologna criteria: a promise unfulfilled? A review of published and unpublished\/ongoing trials. Fertil Steril. 2018;109:104-109.e2 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29198846\/).","journal-title":"Fertil Steril."},{"key":"3296_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.fertnstert.2011.09.051","volume":"96","author":"R Frydman","year":"2011","unstructured":"Frydman R. Poor responders: still a problem. Fertil Steril. 2011;96:1057 (https:\/\/pubmed.ncbi.nlm.nih.gov\/22036047\/).","journal-title":"Fertil Steril."},{"key":"3296_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/humrep\/des118","volume":"27","author":"JS Younis","year":"2012","unstructured":"Younis JS. The Bologna criteria for poor ovarian response; has the job been accomplished? Hum Reprod. 2012;27:1874\u20135 (https:\/\/pubmed.ncbi.nlm.nih.gov\/22473398\/).","journal-title":"Hum Reprod."},{"key":"3296_CR11","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/humrep\/deu135","volume":"29","author":"A Papathanasiou","year":"2014","unstructured":"Papathanasiou A. Implementing the ESHRE \u201cpoor responder\u201d criteria in research studies: methodological implications. Hum Reprod. 2014;29:1835\u20138 (https:\/\/pubmed.ncbi.nlm.nih.gov\/24916434\/).","journal-title":"Hum Reprod."},{"key":"3296_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10815-015-0476-4","volume":"32","author":"A La Marca","year":"2015","unstructured":"La Marca A, Grisendi V, Giulini S, Sighinolfi G, Tirelli A, Argento C, et al. Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. J Assist Reprod Genet. 2015;32:931\u20137 (https:\/\/pubmed.ncbi.nlm.nih.gov\/25925345\/).","journal-title":"J Assist Reprod Genet."},{"key":"3296_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.rbmo.2017.03.009","volume":"34","author":"G Bozdag","year":"2017","unstructured":"Bozdag G, Polat M, Yarali I, Yarali H. Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria. Reprod Biomed Online. 2017;34:639\u201344 (https:\/\/pubmed.ncbi.nlm.nih.gov\/28366519\/).","journal-title":"Reprod Biomed Online."},{"key":"3296_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fendo.2019.00099","volume":"10","author":"SC Esteves","year":"2019","unstructured":"Esteves SC, Carvalho JF, Bento FC, Santos J. A novel predictive model to estimate the number of mature oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization\/intracytoplasmic sperm injection: the ART calculator. Front Endocrinol (Lausanne). 2019;10:99 (https:\/\/pubmed.ncbi.nlm.nih.gov\/30873117\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cen.12573","volume":"82","author":"X Huang","year":"2015","unstructured":"Huang X, Li L, Hong L, Zhou W, Shi H, Zhang H, et al. The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation. Clin Endocrinol (Oxf). 2015;82:577\u201383 (https:\/\/pubmed.ncbi.nlm.nih.gov\/25132286\/).","journal-title":"Clin Endocrinol (Oxf)."},{"key":"3296_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.fertnstert.2018.01.003","volume":"109","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, B\u00fchler K, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;109:644\u201364 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29653717\/).","journal-title":"Fertil Steril."},{"key":"3296_CR17","first-page":"3365","volume":"85","author":"M Perez Mayorga","year":"2000","unstructured":"Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000;85:3365\u20139 (https:\/\/pubmed.ncbi.nlm.nih.gov\/10999835\/).","journal-title":"J Clin Endocrinol Metab."},{"key":"3296_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1477-7827-7-101","volume":"7","author":"C Alviggi","year":"2009","unstructured":"Alviggi C, Humaidan P, Howles CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol. 2009;7:101 (https:\/\/pubmed.ncbi.nlm.nih.gov\/19772632\/).","journal-title":"Reprod Biol Endocrinol."},{"key":"3296_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7827-11-51","volume":"11","author":"C Alviggi","year":"2013","unstructured":"Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013;11:1\u20138 (https:\/\/pubmed.ncbi.nlm.nih.gov\/23725475\/).","journal-title":"Reprod Biol Endocrinol."},{"key":"3296_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-018-0342-1","volume":"16","author":"T Haahr","year":"2018","unstructured":"Haahr T, Esteves SC, Humaidan P. Individualized controlled ovarian stimulation in expected poor-responders: an update. Reprod Biol Endocrinol. 2018;16:1\u20139 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29523204\/).","journal-title":"Reprod Biol Endocrinol."},{"key":"3296_CR21","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/humrep\/dex318","volume":"32","author":"TC Van Tilborg","year":"2017","unstructured":"Van Tilborg TC, Torrance HL, Oudshoorn SC, Eijkemans MJC, Koks CAM, Verhoeve HR, et al. Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: The predicted poor responder. Hum Reprod. 2017;32:2496\u2013505 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/29121326\/).","journal-title":"Hum Reprod."},{"key":"3296_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.23736\/S0031-0808.18.03511-5","volume":"61","author":"A Conforti","year":"2019","unstructured":"Conforti A, Esteves SC, Picarelli S, Iorio G, Rania E, Zullo F, et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. Panminerva Med. 2019;61:24\u20139 (https:\/\/pubmed.ncbi.nlm.nih.gov\/30021418\/).","journal-title":"Panminerva Med."},{"key":"3296_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","volume":"97","author":"P Devroey","year":"2012","unstructured":"Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97:561\u201371 (https:\/\/pubmed.ncbi.nlm.nih.gov\/22244781\/).","journal-title":"Fertil Steril."},{"key":"3296_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7827-8-112","volume":"8","author":"P Lehert","year":"2010","unstructured":"Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol. 2010;8:1\u201312 (https:\/\/pubmed.ncbi.nlm.nih.gov\/20846363\/).","journal-title":"Reprod Biol Endocrinol."},{"key":"3296_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.fertnstert.2007.05.039","volume":"89","author":"PGA Hompes","year":"2008","unstructured":"Hompes PGA, Broekmans FJ, Hoozemans DA, Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008;89:1685\u201393 (https:\/\/pubmed.ncbi.nlm.nih.gov\/17681325\/).","journal-title":"Fertil Steril."},{"key":"3296_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fendo.2018.00361","volume":"9","author":"P Drakopoulos","year":"2018","unstructured":"Drakopoulos P, Santos-Ribeiro S, Bosch E, Garcia-Velasco J, Blockeel C, Romito A, et al. The effect of dose adjustments in a subsequent cycle of women with suboptimal response following conventional ovarian stimulation. Front Endocrinol (Lausanne). 2018;9:361 (https:\/\/pubmed.ncbi.nlm.nih.gov\/30083131\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.fpc.0000167330.92786.5e","volume":"15","author":"HM Behre","year":"2005","unstructured":"Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwa\u00dfer P, et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics. 2005;15:451\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/15970792\/).","journal-title":"Pharmacogenet Genomics."},{"key":"3296_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/humupd\/dmy019","volume":"24","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Santi D, Esteves SC, Andersen CY, Humaidan P, et al. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update. 2018;24:599\u2013614 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29924306\/).","journal-title":"Hum Reprod Update."},{"key":"3296_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1472-6483(10)60865-6","volume":"12","author":"C Alviggi","year":"2006","unstructured":"Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online. 2006;12:221\u201333 (https:\/\/pubmed.ncbi.nlm.nih.gov\/16478591\/).","journal-title":"Reprod Biomed Online."},{"key":"3296_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.fertnstert.2006.06.059","volume":"87","author":"G Ruvolo","year":"2007","unstructured":"Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2007;87:542\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/17126339\/).","journal-title":"Fertil Steril."},{"key":"3296_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/humrep\/deh625","volume":"20","author":"G De Placido","year":"2005","unstructured":"De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod. 2005;20:390\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/15576390\/).","journal-title":"Hum Reprod."},{"key":"3296_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.fertnstert.2004.06.041","volume":"82","author":"AP Ferraretti","year":"2004","unstructured":"Ferraretti AP, Gianaroli L, Magli MC, D\u2019angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82:1521\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/15589853\/).","journal-title":"Fertil Steril."},{"key":"3296_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1472-6483(10)61610-0","volume":"5","author":"F Lisi","year":"2002","unstructured":"Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, et al. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online. 2002;5:104\u20138 (https:\/\/pubmed.ncbi.nlm.nih.gov\/12419032\/).","journal-title":"Reprod Biomed Online."},{"key":"3296_CR34","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.fertnstert.2016.03.002","volume":"105","author":"FM Ubaldi","year":"2016","unstructured":"Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105:1488-1495.e1 (https:\/\/pubmed.ncbi.nlm.nih.gov\/27020168\/).","journal-title":"Fertil Steril."},{"key":"3296_CR35","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/humrep\/dey217","volume":"33","author":"D Cimadomo","year":"2018","unstructured":"Cimadomo D, Vaiarelli A, Colamaria S, Trabucco E, Alviggi C, Venturella R, et al. Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018;33:1442\u20138 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29912374\/).","journal-title":"Hum Reprod."},{"key":"3296_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/GCO.0000000000000452","volume":"30","author":"A Vaiarelli","year":"2018","unstructured":"Vaiarelli A, Cimadomo D, Ubaldi N, Rienzi L, Ubaldi FM. What is new in the management of poor ovarian response in IVF? Curr Opin Obstet Gynecol. 2018;30:155\u201362 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29664789\/).","journal-title":"Curr Opin Obstet Gynecol."},{"key":"3296_CR37","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. Human reproduction open. 2020, 1\u201313. http:\/\/www.eshre.eu\/Guidelines-and-Legal\/Guidelines."},{"key":"3296_CR38","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/humrep\/deab152","volume":"36","author":"SC Esteves","year":"2021","unstructured":"Esteves SC, Yarali H, Vuong LN, Carvalho JF, \u00d6zbek IY, Polat M, et al. Cumulative delivery rate per aspiration IVF\/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. Hum Reprod. 2021;36:2157\u201369 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/34179973\/).","journal-title":"Hum Reprod."},{"key":"3296_CR39","doi-asserted-by":"publisher","first-page":"103852","DOI":"10.1016\/j.rbmo.2024.103852","volume":"49","author":"A Hochberg","year":"2024","unstructured":"Hochberg A, Dahan MH, Yarali H, Vuong LN, Esteves SC. Clinical factors associated with unexpected poor or suboptimal response in Poseidon criteria patients. Reprod Biomed Online. 2024;49:103852 (https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648324000415).","journal-title":"Reprod Biomed Online."},{"key":"3296_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1472-6483(10)62164-5","volume":"6","author":"U Ulug","year":"2003","unstructured":"Ulug U, Ben-Shlomo I, Turan E, Erden HF, Ali Akman M, Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online. 2003;6:439\u201343 (https:\/\/pubmed.ncbi.nlm.nih.gov\/12831590\/).","journal-title":"Reprod Biomed Online."},{"key":"3296_CR41","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/humrep\/der106","volume":"26","author":"SK Sunkara","year":"2011","unstructured":"Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26:1768\u201374 (https:\/\/pubmed.ncbi.nlm.nih.gov\/21558332\/).","journal-title":"Hum Reprod."},{"key":"3296_CR42","first-page":"370","volume":"31","author":"P Drakopoulos","year":"2016","unstructured":"Drakopoulos P, Blockeel C, Stoop D, Camus M, De Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31:370\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/26724797\/).","journal-title":"Hum Reprod"},{"key":"3296_CR43","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1093\/humrep\/dem285","volume":"22","author":"G Nargund","year":"2007","unstructured":"Nargund G, Fauser BCJM, Macklon NS, Ombelet W, Nygren K, Frydman R. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod. 2007;22:2801\u20134 (https:\/\/pubmed.ncbi.nlm.nih.gov\/17855409\/).","journal-title":"Hum Reprod."},{"key":"3296_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fendo.2019.00917","volume":"10","author":"SC Esteves","year":"2020","unstructured":"Esteves SC, Yarali H, Ubaldi FM, Carvalho JF, Bento FC, Vaiarelli A, et al. Validation of ART calculator for predicting the number of metaphase II oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization\/intracytoplasmic sperm injection. Front Endocrinol (Lausanne). 2020;10:917 (https:\/\/pubmed.ncbi.nlm.nih.gov\/32038484\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR45","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.fertnstert.2009.04.040","volume":"94","author":"FJM Broekmans","year":"2010","unstructured":"Broekmans FJM, De Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94:1044\u201351 (https:\/\/pubmed.ncbi.nlm.nih.gov\/19589513\/).","journal-title":"Fertil Steril."},{"key":"3296_CR46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.fertnstert.2014.10.052","volume":"103","author":"L Craciunas","year":"2015","unstructured":"Craciunas L, Roberts SA, Yates AP, Smith A, Fitzgerald C, Pemberton PW. Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antim\u00fcllerian hormone measurement. Fertil Steril. 2015;103:554-559.e1 (https:\/\/pubmed.ncbi.nlm.nih.gov\/25487749\/).","journal-title":"Fertil Steril."},{"key":"3296_CR47","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/humrep\/deab056","volume":"36","author":"SC Esteves","year":"2021","unstructured":"Esteves SC, Yarali H, Vuong LN, Carvalho JF, \u00d6zbek \u0130Y, Polat M, et al. Antral follicle count and anti-M\u00fcllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. Hum Reprod. 2021;36:1530\u201341 (https:\/\/pubmed.ncbi.nlm.nih.gov\/33822057\/).","journal-title":"Hum Reprod."},{"key":"3296_CR48","doi-asserted-by":"publisher","first-page":"630550","DOI":"10.3389\/fendo.2021.630550","volume":"12","author":"SC Esteves","year":"2021","unstructured":"Esteves SC, Yarali H, Vuong LN, Carvalho JF, \u00d6zbek \u0130Y, Polat M, et al. Low prognosis by the POSEIDON criteria in women undergoing assisted reproductive technology: a multicenter and multinational prevalence study of over 13,000 patients. Front Endocrinol (Lausanne). 2021;12:630550 (https:\/\/pubmed.ncbi.nlm.nih.gov\/33790862\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR49","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/humrep\/deac113","volume":"37","author":"X Liu","year":"2022","unstructured":"Liu X, Wen W, Wang T, Tian L, Li N, Sun T, et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Hum Reprod. 2022;37:1806\u201315 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/35595197\/).","journal-title":"Hum Reprod."},{"key":"3296_CR50","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/humrep\/dex321","volume":"32","author":"TC Van Tilborg","year":"2017","unstructured":"Van Tilborg TC, Oudshoorn SC, Eijkemans MJC, Mochtar MH, Van Golde RJT, Hoek A, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF\/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017;32:2485\u201395 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/29121350\/).","journal-title":"Hum Reprod."},{"key":"3296_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fendo.2019.00094","volume":"10","author":"LR Bernstein","year":"2019","unstructured":"Bernstein LR, Nawroth F, Bedoschi GM, Cimadomo D, Ubaldi FM, Vaiarelli A, et al. Advanced maternal age in IVF: still a challenge? The present and the future of its treatment. Front Endocrinol. 2019;10:94.","journal-title":"Front Endocrinol."},{"key":"3296_CR52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/humrep\/des049","volume":"27","author":"SL Chen","year":"2012","unstructured":"Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod. 2012;27:1351\u20136 (https:\/\/pubmed.ncbi.nlm.nih.gov\/22419746\/).","journal-title":"Hum Reprod."},{"key":"3296_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","volume":"69","author":"R de Le\u00e3o","year":"2014","unstructured":"de Le\u00e3o R, BF, Esteves SC,. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo). 2014;69:279\u201393 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/24714837\/).","journal-title":"Clinics (Sao Paulo)."},{"key":"3296_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12958-021-00768-3","volume":"19","author":"KF B\u00fchler","year":"2021","unstructured":"B\u00fchler KF, Fischer R, Verpillat P, Allignol A, Guedes S, Boutmy E, et al. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany. Reprod Biol Endocrinol. 2021;19:90 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/34134695\/).","journal-title":"Reprod Biol Endocrinol."},{"key":"3296_CR55","doi-asserted-by":"publisher","first-page":"797365","DOI":"10.3389\/fendo.2021.797365","volume":"12","author":"A Conforti","year":"2022","unstructured":"Conforti A, T\u00fcttelmann F, Alviggi C, Behre HM, Fischer R, Hu L, et al. Effect of genetic variants of gonadotropins and their receptors on ovarian stimulation outcomes: a delphi consensus. Front Endocrinol (Lausanne). 2022;12:797365 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/35178027\/).","journal-title":"Front Endocrinol (Lausanne)."},{"key":"3296_CR56","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/humrep\/deab068","volume":"36","author":"NP Polyzos","year":"2021","unstructured":"Polyzos NP, Neves AR, Drakopoulos P, Spits C, Alvaro Mercadal B, Garcia S, et al. The effect of polymorphisms in FSHR and FSHB genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. Hum Reprod. 2021;36:1711\u201321 (https:\/\/pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca\/33889959\/).","journal-title":"Hum Reprod."},{"key":"3296_CR57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/humrep\/dev342","volume":"31","author":"I Lindgren","year":"2016","unstructured":"Lindgren I, Baath M, Uvebrant K, Dejmek A, Kjaer L, Henic E, et al. Combined assessment of polymorphisms in the LHCGR and FSHR genes predict chance of pregnancy after in vitro fertilization. Hum Reprod. 2016;31:672\u201383 (https:\/\/pubmed.ncbi.nlm.nih.gov\/26769719\/).","journal-title":"Hum Reprod."},{"key":"3296_CR58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/09513590.2017.1291614","volume":"33","author":"J Subir\u00e1","year":"2017","unstructured":"Subir\u00e1 J, Alberola-Rubio J, N\u00fa\u00f1ez MJ, Escriv\u00e1 AM, Pellicer A, Monta\u00f1ana V, et al. Inter-cycle and inter-observer variability of the antral follicle count in routine clinical practice. Gynecol Endocrinol. 2017;33:515\u20138 (https:\/\/pubmed-ncbi-nlm-nih-gov.sheba.idm.oclc.org\/28277111\/).","journal-title":"Gynecol Endocrinol."},{"key":"3296_CR59","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1515\/cclm-2014-0022","volume":"52","author":"D Gassner","year":"2014","unstructured":"Gassner D, Jung R. First fully automated immunoassay for anti-M\u00fcllerian hormone. Clin Chem Lab Med. 2014;52:1143\u201352 (https:\/\/pubmed-ncbi-nlm-nih-gov.sheba.idm.oclc.org\/24622790\/).","journal-title":"Clin Chem Lab Med"},{"key":"3296_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/09513590.2017.1369515","volume":"34","author":"B Alvaro Mercadal","year":"2018","unstructured":"Alvaro Mercadal B, Rodr\u00edguez I, Arroyo G, Mart\u00ednez F, Barri PN, Coroleu B. Characterization of a suboptimal IVF population and clinical outcome after two IVF cycles. Gynecol Endocrinol. 2018;34:125\u20138 (https:\/\/pubmed.ncbi.nlm.nih.gov\/28868939\/).","journal-title":"Gynecol Endocrinol."}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-024-03296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-024-03296-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-024-03296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:04:42Z","timestamp":1736298282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-024-03296-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3296"],"URL":"https:\/\/doi.org\/10.1007\/s10815-024-03296-2","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study received ethical approval from the institutions\u2019 ethics committees: Instituto Investiga, Brazil (CAAE 26429219.0.0000.5599); Hacettepe University, Turkey (KA-180070); and My Duc Hospital, Vietnam (05\/18\/DD-BVMD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived due to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"MHD received unrestricted research grants from Merck Serono and Ferring. HY declares receipt of payment for lectures from Merck and Ferring. LNV receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD), and Ferring and research grants from MSD and Ferring. SCE declares receipt of unrestricted research grants from Merck and lecture fees from Merck and MedEA. AH has no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}